CRISPR 治療公司

SecurityCRSP / CRISPR Therapeutics AG
InstitutionCitigroup Inc
Latest Disclosed Ownership21,970 shares
Latest Disclosed Value $ 1,045,113
Citigroup Inc ownership in CRSP / CRISPR Therapeutics AG

On May 11, 2026 - Citigroup Inc filed a 13F-HR form disclosing ownership of 21,970 shares of CRISPR Therapeutics AG (US:CRSP) valued at $1,045,113 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 132,693 shares of CRISPR Therapeutics AG. This represents a change in shares of -83.44% during the quarter. The current value of the position is $1,251,192 USD.

Citigroup Inc has a history of taking positions in derivatives of the underlying security (CRSP) in the form of stock options. The firm currently holds call options representing 79,000 of underlying shares valued at $3,758,030 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

CRSP / CRISPR Therapeutics AG Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 21,970 -110,723 -83.44 1,045 -84.98 0.0004
2026-02-13 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 132,693 72,204 119.37 6,958 77.50 0.0031
2025-11-10 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 60,489 -66,403 -52.33 3,920 -36.49 0.0017
2025-08-11 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 126,892 -78,756 -38.30 6,172 -11.80 0.0030
2025-05-12 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 205,648 95,292 86.35 6,998 61.13 0.0036
2025-02-12 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 110,356 85,934 351.87 4,344 278.64 0.0026
2024-11-12 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 24,422 -13,682 -35.91 1,147 -44.24 0.0007
2024-08-12 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 38,104 -63,365 -62.45 2,058 -70.26 0.0013
2024-05-10 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 101,469 -9,616 -8.66 6,916 -0.53 0.0045
2024-02-09 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 111,085 -1,026 -0.92 6,954 36.65 0.0049
2023-12-06 2023-09-30 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 112,111 3,617 3.33 5,089 -16.45 0.0038
2023-11-09 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 112,111 3,617 5,089 0.0015
2023-08-10 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 108,494 -82,521 -43.20 6,091 -29.51 0.0040
2023-05-11 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 191,015 66,067 52.88 8,640 70.09 0.0061
2023-02-09 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 124,948 8,354 7.17 5,079 -33.34 0.0040
2022-11-10 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 116,594 25,340 27.77 7,619 37.38 0.0055
2022-08-10 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 91,254 60,876 200.40 5,546 190.67 0.0041
2022-05-12 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 30,378 -410 -1.33 1,908 -18.18 0.0012
2022-02-10 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 30,788 2,275 7.98 2,332 -26.94 0.0012
2021-11-10 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 28,513 -4,648 -14.02 3,192 -40.54 0.0019
2021-08-10 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 33,161 7,135 27.41 5,368 69.28 0.0032
2021-05-13 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 26,026 4,765 22.41 3,171 -2.61 0.0021
2021-02-11 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 21,261 -14,151 -39.96 3,256 9.96 0.0019
2020-11-12 2020-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 35,412 -9,802 -21.68 2,961 -10.89 0.0019
2020-08-12 2020-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 45,214 -14,489 -24.27 3,323 31.24 0.0026
2020-05-12 2020-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 59,703 34,625 138.07 2,532 65.82 0.0023
2020-02-12 2019-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 25,078 15,935 174.29 1,527 307.20 0.0011
2019-11-08 2019-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 9,143 -5,347 -36.90 375 -45.10 0.0003
2019-08-12 2019-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 14,490 -2,466 -14.54 683 12.89 0.0006
2019-05-13 2019-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 16,956 -42 -0.25 605 24.49 0.0006
2019-02-12 2018-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 16,998 5,603 49.17 486 -3.76 0.0005
2018-11-13 2018-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 11,395 1,278 12.63 505 -15.13 0.0005
2018-08-10 2018-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 10,117 8,795 665.28 595 875.41 0.0005
2018-05-11 2018-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,322 17 1.30 61 103.33 0.0001
2018-02-12 2017-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,305 1,295 12,950.00 30 0.0000
2017-11-13 2017-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 10 10 0 0.0000
2017-08-11 2017-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 0 -100 -100.00 0 -100.00
2017-05-12 2017-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 100 100 2 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-11 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 79,000 3,758 n/a n/a n/a
2025-11-10 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-08-11 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 55,000 0.00 2,675 42.97 n/a n/a n/a
2025-05-12 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 55,000 169.61 1,872 133.29 n/a n/a n/a
2025-02-12 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 20,400 803 n/a n/a n/a
2023-08-10 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-05-11 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 30,000 -62.50 1,357 -58.30 n/a n/a n/a
2023-02-09 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 80,000 14.29 3,252 -28.92 n/a n/a n/a
2022-11-10 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 70,000 4,575 n/a n/a n/a
2021-05-13 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 0 -100.00 0 -100.00 n/a n/a n/a
2021-02-11 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 96,300 250.18 14,744 541.04 n/a n/a n/a
2020-11-12 2020-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 27,500 -17.17 2,300 -5.74 n/a n/a n/a
2020-08-12 2020-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 33,200 -23.85 2,440 31.96 n/a n/a n/a
2020-05-12 2020-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 43,600 -13.49 1,849 -39.77 n/a n/a n/a
2020-02-12 2019-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 50,400 59.49 3,070 137.07 n/a n/a n/a
2019-11-08 2019-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 31,600 125.71 1,295 96.51 n/a n/a n/a
2019-08-12 2019-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 14,000 52.17 659 100.30 n/a n/a n/a
2019-05-13 2019-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 9,200 -53.77 329 -42.18 n/a n/a n/a
2019-02-12 2018-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 19,900 275.47 569 142.13 n/a n/a n/a
2018-11-13 2018-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 5,300 235 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-11-10 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-08-11 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 33,200 1,615 n/a n/a n/a
2025-05-12 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-02-12 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 20,400 803 n/a n/a n/a
2023-08-10 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 0 -100.00 0 -100.00 n/a n/a n/a
2023-05-11 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 30,000 1,357 n/a n/a n/a
2023-02-09 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 0 -100.00 0 -100.00 n/a n/a n/a
2022-11-10 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 20,000 1,307 n/a n/a n/a
2021-05-13 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 0 -100.00 0 -100.00 n/a n/a n/a
2021-02-11 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 86,100 51.58 13,183 177.48 n/a n/a n/a
2020-11-12 2020-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 56,800 -45.44 4,751 -37.90 n/a n/a n/a
2020-08-12 2020-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 104,100 -17.32 7,650 43.29 n/a n/a n/a
2020-05-12 2020-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 125,900 70.37 5,339 18.62 n/a n/a n/a
2020-02-12 2019-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 73,900 114.20 4,501 218.32 n/a n/a n/a
2019-11-08 2019-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 34,500 -31.95 1,414 -40.79 n/a n/a n/a
2019-08-12 2019-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 50,700 115.74 2,388 184.62 n/a n/a n/a
2019-05-13 2019-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 23,500 158.24 839 222.69 n/a n/a n/a
2019-02-12 2018-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 9,100 93.62 260 25.00 n/a n/a n/a
2018-11-13 2018-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 4,700 208 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.